India Launches Awiqli: World's First Once-Weekly Insulin for Diabetes Care
On 9 July 2026, India became one of the first countries to roll out Awiqli, the world's first once-weekly basal insulin. Here is a detailed, exam-oriented look at what the drug is, how it works, and why it matters.
On 9 July 2026, India launched Awiqli, described as the world's first once-weekly basal insulin. The product contains the molecule insulin icodec and is marketed by the Danish pharmaceutical company Novo Nordisk. The launch is being seen as a major milestone in diabetes management, since it replaces the daily injections that most insulin-dependent patients currently need with a single weekly dose.
A basal insulin is a long-acting insulin that keeps blood-sugar levels steady between meals and overnight. Conventional basal insulins have to be injected once or twice a day. Awiqli, based on insulin icodec, is engineered to be released slowly and steadily over about a week, which means a person may need only 52 injections a year instead of 365 or more. This can dramatically improve treatment adherence and quality of life.
India has one of the largest diabetic populations in the world, with tens of millions of people living with type 1 and type 2 diabetes. Poor adherence to daily insulin is a well-known problem that leads to complications such as kidney disease, nerve damage, and cardiovascular illness. By reducing the injection burden, a once-weekly insulin could help patients stay on treatment more consistently, especially in rural areas where regular dosing is harder to maintain.
The approval and launch of Awiqli in India also reflect the country's growing role in adopting advanced biopharmaceutical therapies quickly. However, doctors caution that a once-weekly insulin must be used under proper medical supervision, with correct dose adjustment, because a longer-acting formulation also means that the effect of any dosing error lasts longer. Patient education on hypoglycaemia (low blood sugar) awareness remains essential.
Key Points (मुख्य बिंदु)
- Product: Awiqli — the world's first once-weekly basal insulin.
- Molecule: Insulin icodec.
- Manufacturer: Novo Nordisk (Denmark).
- Launch date in India: 9 July 2026.
- Significance: One weekly injection replaces daily insulin shots, improving adherence.
📝 Exam Focus (परीक्षा की दृष्टि से महत्वपूर्ण)
- Awiqli is the world's first once-weekly basal insulin.
- It contains insulin icodec and is made by Novo Nordisk, a Danish company.
- Basal insulin controls blood sugar between meals and during sleep.
- Approx. 52 injections per year instead of 365+, improving patient adherence.
